Antiplatelet effects of clopidogrel dose adjustment (75 mg/d vs 150 mg/d) after carotid stenting

Journal of Vascular Surgery

Volumn 60, Issue 2, 2014, Pages 428-435

  González, Alejandro ^a   Moniche, Francisco ^a   Cayuela, Aurelio ^a   Gonzalez Marcos, Jose Ramón ^a   Mayol, Antonio ^a   Montaner, Joan ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b Instituto de Biomedicina de Sevilla   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CAROTID ARTERY STENTING; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DEATH; DRUG DOSE COMPARISON; DRUG MEGADOSE; EMBOLIC PROTECTION DEVICE; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; MIDDLE AGED; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDARD; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

AGED; ANGIOPLASTY; BLOOD PLATELETS; CAROTID ARTERY DISEASES; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; SPAIN; STENTS; STROKE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84905101321     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2014.01.068     Document Type: Article

References (31)

1. D.L. Bhatt, S.R. Kapadia, C.T. Bajzer, D.P. Chew, K.M. Ziada, and D. Mukherjee et al. Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting J Invasive Cardiol 13 2001 767 771
2. S.R. Steinhubl, P.B. Berger, J.T. Mann 3rd, E.T. Fry, A. DeLago, and C. Wilmer et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2002 2411 2420
3. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE): CAPRIE Steering Committee Lancet 348 1996 1329 1339
4. F.M. McKevitt, M.S. Randall, T.J. Cleveland, P.A. Gaines, K.T. Tan, and G.S. Venables The benefits of combined anti-platelet treatment in carotid artery stenting Eur J Vasc Endovasc Surg 29 2005 522 527
5. S. Prabhakaran, K.R. Wells, V.H. Lee, C.A. Flaherty, and D.K. Lopes Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting AJNR Am J Neuroradiol 29 2008 281 285
6. S. Muller-Schunk, J. Linn, N. Peters, M. Spannagl, M. Deisenberg, and H. Brückmann et al. Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supraaortic stenting AJNR Am J Neuroradiol 29 2008 786 789
7. D.H. Lee, A. Arat, H. Morsi, H. Shaltoni, J.R. Harris, and M.E. Mawad Antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience AJNR Am J Neuroradiol 29 2008 1389 1394
8. J.T. Fifi, C. Brockington, J. Narang, W. Leesch, S.L. Ewing, and H. Bennet et al. Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting AJNR Am J Neuroradiol 34 2012 716 720
9. H. Maruyama, H. Takeda, T. Dembo, H. Nagoya, Y. Kato, and T. Fukuoka et al. Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y12 assay Intern Med 50 2011 695 698
10. T.J. Song, S.H. Suh, P.K. Min, D.J. Kim, B.M. Kim, and J.H. Heo et al. The influence of anti-platelet resistance on the development of cerebral ischemic lesion after carotid artery stenting Yonsei Med J 54 2013 288 294
11. G.C. Sorkin, T.M. Dumont, M.M. Wach, J.L. Eller, M. Mokin, and S.K. Natarajan et al. Carotid artery stenting outcomes: do they correlate with antiplatelet response assays? J Neurointerv Surg 6 2014 373 378
12. M.J. Price, J.L. Coleman, S.R. Steinhubl, G.B. Wong, C.P. Cannon, and P.S. Teirstein Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers Am J Cardiol 98 2006 681 684
13. G. Patti, D. Grieco, G. Dicuonzo, V. Pasceri, A. Nusca, and G. Di Sciascio High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) randomized study J Am Coll Cardiol 57 2011 771 778
14. R. Marcucci, A.M. Gori, R. Paniccia, B. Giusti, S. Valente, and C. Giglioli et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
15. S.R. Mehta, J.F. Tanquay, J.W. Eikelboom, S.S. Jolly, C.D. Joyner, and C.B. Granger et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomized factorial trial Lancet 376 2010 1233 1243
16. A.D. Michelson, A.L. Frelinger 3rd, E. Braunwald, W.E. Downey, D.J. Angiolillo, and N.P. Xenopoulos et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Eur Heart J 30 2009 1753 1763
17. H. Neubauer, S. Lask, A. Engelhardt, and A. Mügge How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification Thromb Haemost 99 2008 357 362
18. B. Aleil, L. Jacquemin, F. De Poli, M. Zaehringer, J.P. Collet, and G. Montalescot et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study JACC Cardiovasc Interv 1 2008 631 638
19. D. Angiolillo, M. Costa, S. Shoemaker, B. Desai, E. Bernardo, and Y. Suzuki et al. Functional effects of high clopidogrel maintenance dosing in patients with inadequate plate-let inhibition on standard dose treatment Am J Cardiol 101 2008 440 445
20. S. Matetzky, P. Fefer, B. Shenkman, D. Varon, N. Savion, and H. Hod Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction Am J Cardiol 102 2008 524 529
21. M. Ho, T. Maddox, L. Wang, S.D. Fihn, R.L. Jesse, and E.D. Peterson et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 2009 937 944
22. J. Matías-Guiu, J.M. Ferro, J. Alvarez-Sabín, F. Torres, M.D. Jiménez, A. Lago TACIP Investigators Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial Stroke 34 2003 840 848
23. T.G. Brott, J.L. Halperin, S. Abbara, J.M. Bacharach, J.D. Barr, and R.L. Bush et al. ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Developed in collaboration with the American Academy of Neurology and Society of Cardiovascular Computed Tomography Catheter Cardiovasc Interv 81 2013 E76 123
24. M.J. Price, S. Endemann, R.R. Gollapudi, R. Valencia, C.T. Stinis, and J.P. Levisay et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of- care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
25. P. Piñero, A. González, A. Mayol, E. Martínez, J.R. González-Marcos, and F. Boza et al. Silent ischemia after neuroprotected percutaneous carotid stenting: a diffusion-weighted MRI study AJNR Am J Neuroradiol 27 2006 1338 1345
26. H.J. Barnett, D.W. Taylor, M. Eliasziw, A.J. Fox, G.G. Ferguson, and R.B. Haynes et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators N Engl J Med 339 1998 1415 1425
27. M. Price, P. Berger, P. Teirstein, J.F. Tanguay, D.J. Angiolillo, and D. Spriggs et al. Standard vs high dose clopidogrel based on platelet function testing after percutaneous coronary intervention. The GRAVITAS randomized trial JAMA 305 2011 1097 1105
28. G. Patti, F. Tomai, R. Melfi, E. Ricottini, M. Macrì, and P. Sedati et al. Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) study J Am Coll Cardiol 61 2013 1379 1387
29. V.D. Heyden, J. Van Wekum, C.M. Hackeng, J.C. Kelder, N.J. Breet, and V.H. Deneer et al. High versus standard clopidogrel loading in patients undergoing carotid artery stenting prior to cardiac surgery to assess the number of microemboli detected with transcranial Doppler: results of the randomized IMPACT trial J Cardiovasc Surg (Torino) 54 2013 337 347
30. C. Goh, L. Churilov, P. Mitchell, R. Dowling, and B. Yan Clopidogrel hyper-response and bleeding risk in neurointerventional procedures AJNR Am J Neuroradiol 34 2012 721 726
31. J.E. Delgado Almandoz, B.M. Crandall, J.M. Scholz, J.L. Fease, R.E. Anderson, and Y. Kadkhodayan et al. Last-recorded P2Y12 reaction units value is strongly associated with thromboembolic and hemorrhagic complications occurring up to 6 months after treatment in patients with cerebral aneurysms treated with the Pipeline embolization device AJNR Am J Neuroradiol 35 2014 128 135